Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 40Recurrence 9Neoplasms, Plasma Cell 7Waldenstrom Macroglobulinemia 3Neoplasms 3Lymphoma, B-Cell 3Burkitt Lymphoma 3Sarcoma, Kaposi 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Renal Insufficiency 1Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myeloproliferative Disorders 1Multi-centric Castleman's Disease 1Leukemia, Myeloid, Acute 1Intraocular Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Hematologic Diseases 1Epstein-Barr Virus Infections 1Disease Progression 1Disease 1Central Nervous System Neoplasms 1Amyloidosis 1

Interventions

Cyclophosphamide 17fludarabine 16fludarabine phosphate 11Azacitidine 9venetoclax 8Rituximab 8Nivolumab 7Melphalan 7Tacrolimus 6Cytarabine 6Specimen Handling 5Sirolimus 5Ipilimumab 5Clofarabine 5CTLA-4 Antigen 5Antilymphocyte Serum 5belinostat 4aldesleukin 4Thiotepa 4Standard of Care 4Practice Guidelines as Topic 4Mycophenolic Acid 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interleukin-2 4Granulocyte Colony-Stimulating Factor 4Dexamethasone 4Busulfan 4Bortezomib 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hematologic Neoplasms × pomalidomide × Clear all
NCT05828459 2025-03-20

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Onward Therapeutics

Phase 1 Recruiting
150 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡